ArticleCase reports in oncology

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma.

Dahlia Fedele et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.